MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...
Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...
A recent health news roundup explores legal, financial, and strategic developments. Highlights include Robert F. Kennedy ...
This report covers recent health news, including Robert F. Kennedy Jr.'s legal fees from Merck litigations, rejections of a ...
Merck KGaA (OTCMKTS:MKGAF – Get Free Report)’s stock price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $147.57 and traded as low as ...
6don MSN
They call themselves Speed to Market, a group of life sciences and real estate professionals who find, build and sell manufacturing space for biotech employers around Philadelphia. During the COVID ...
According to Evaluate Pharma, China's growing influence in pharmaceutical R&D is a key theme to watch in 2025. The pharma ...
Charlottesville life sciences company Vion Biosciences has tapped a new its chief strategy and development officer with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback